BiotechTube

LY3041658 + Placebo

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Skin Diseases

Conditions

Skin Diseases, Psoriasis

Trial Timeline

Nov 8, 2016 → Mar 19, 2019

NCT ID
NCT02896868

About LY3041658 + Placebo

LY3041658 + Placebo is a phase 1 stage product being developed by Eli Lilly for Skin Diseases. The current trial status is completed. This product is registered under clinical trial identifier NCT02896868. Target conditions include Skin Diseases, Psoriasis.

What happened to similar drugs?

16 of 20 similar drugs in Skin Diseases were approved

Approved (16) Terminated (4) Active (4)
✅Vancomycin + Daptomycin + Semi-Synthetic PenicillinMerckApproved
✅Daptomycin + Standard of Care (SOC)MerckApproved
✅Daptomycin + VancomycinMerckApproved
✅Daptomycin + VancomycinMerckApproved
✅DaptomycinNovartisApproved
✅Tigecycline + ampicillin-sulbactamPfizerApproved
✅linezolid + vancomycinPfizerApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02896868Phase 1Completed

Competing Products

20 competing products in Skin Diseases

See all competitors
ProductCompanyStageHype Score
[203Pb]VMT01 + [212Pb]VMT01 + NivolumabPerspective TherapeuticsPhase 1/2
33
[203Pb]VMT01 + [68Ga]VMT02Perspective TherapeuticsPhase 1
23
Mupirocin Calcium Cream, 2% + Bactroban® Cream + Cream vehicle of test productSun PharmaceuticalPhase 1
29
DSP-9632P 27.5 mg + DSP-9632P 82.5 mg + Placebo + DSP-9632P 55.0 mg + Levodopa formulationSumitomo PharmaPhase 1
29
levofloxacinJohnson & JohnsonPhase 2/3
38
Moisturizer A, F#9155-005Johnson & JohnsonPre-clinical
26
levofloxacinJohnson & JohnsonPhase 3
40
CeftobiproleJohnson & JohnsonPhase 1
29
Natural Killer Cell Therapy + Universal Donor Expanded TGF-beta-imprinted NK CellsJohnson & JohnsonPhase 1
36
LevofloxacinJohnson & JohnsonPhase 3
40
CeftobiproleJohnson & JohnsonPhase 1
29
Levodopa-carbidopa intestinal gelAbbViePhase 3
40
IressaAstraZenecaPhase 2
35
Daptomycin + VancomycinAstraZenecaPhase 3
40
SarizotanMerckPre-clinical
18
Pembrolizumab + EDP1503MerckPhase 2
27
testosterone gel + Comparator: placeboMerckPhase 1
29
LNS8801 + Pembrolizumab + Chemotherapy (dacarbazine or temozolomide) + Immunotherapy (Pembrolizumab) + Immunotherapy (nivolumab and relatlimab) + Immunotherapy (ipilimumab and nivolumab)MerckPhase 2/3
45
Vancomycin + Daptomycin + Semi-Synthetic PenicillinMerckApproved
35
Pembrolizumab + VismodegibMerckPhase 1/2
32